Patient and transplant characteristics in the whole cohort and stratified by donor type
| Characteristic . | Total N = 1652 . | MUD N = 1106 . | MMUD N = 340 . | Haplo N = 206 . | P value . |
|---|---|---|---|---|---|
| Median age at transplant, y (IQR) | 20.4 (11.2-40.1) | 21 (11.7-42.3) | 17.8 (10.4-34.8) | 20.9 (10.7-37.5) | .016 |
| Sex, n (%) | .756 | ||||
| Male | 953 (58) | 631 (57) | 201 (59) | 121 (59) | |
| Female | 699 (42) | 475 (43) | 139 (41) | 85 (41) | |
| KPS, n (%) | .319 | ||||
| ≥90 | 1116 (73) | 753 (74) | 232 (74) | 131 (67) | |
| <90 | 412 (27) | 267 (26) | 80 (26) | 65 (33) | |
| Missing | 124 | 86 | 28 | 10 | |
| Year of transplant, median (IQR) | 2017 (2014-2019) | 2017 (2014-2019) | 2016 (2014-2019) | 2018 (2017-2020) | <.001 |
| Interval diagnosis to transplant in months, median (IQR) | 8.7 (4.8-16.6) | 8.1 (4.3-14.3) | 10.4 (6.2-19.6) | 9.2 (4.8-18.5) | <.001 |
| Donor–recipient CMV serostatus, n (%) | <.001 | ||||
| Positive/positive | 740 (46) | 436 (40) | 164 (50) | 140 (72) | |
| Positive/negative | 97 (6) | 66 (6) | 20 (6) | 11 (6) | |
| Negative/positive | 397 (25) | 277 (26) | 96 (30) | 24 (12) | |
| Negative/negative | 370 (23) | 304 (28) | 46 (14) | 20 (10) | |
| Missing | 48 | 23 | 14 | 11 | |
| HCT-CI, n (%) | .522 | ||||
| Low | 894 (69) | 597 (69) | 178 (69) | 119 (70) | |
| Intermediate | 201 (16) | 126 (15) | 48 (18) | 27 (16) | |
| High | 194 (15) | 136 (16) | 33 (13) | 25 (14) | |
| Missing | 363 | 247 | 81 | 35 | |
| Median age of donor, y (range) | 29.4 (23.6-36.8) | 28.2 (23.4-34.4) | 29.5 (23.6-37.5) | 36.3 (27.2-45.9) | <.001 |
| Female donor to male recipient, n (%) | 254 (16) | 129 (12) | 71 (21) | 54 (26) | <.001 |
| TBI in conditioning, n (%) | <.001 | ||||
| Yes | 495 (31) | 253 (23) | 103 (31) | 139 (69) | |
| No | 1122 (69) | 834 (77) | 224 (69) | 64 (31) | |
| Missing | 35 | 19 | 13 | 3 | |
| TBI dose, n (%) | <.001 | ||||
| 2 Gy | 430 (87) | 239 (94) | 87 (84) | 104 (75) | |
| >2 Gy | 65 (13) | 14 (6) | 16 (16) | 35 (25) | |
| Conditioning regime,∗ n (%) | <.001 | ||||
| Flu + Cy + ATG + TBI | 287 (18) | 156 (14) | 56 (17) | 75 (36.5) | |
| Flu + Cy + ATG | 402 (24) | 291 (26) | 84 (25) | 27 (13) | |
| Flu + Cy + TBI | 131 (8) | 56 (5) | 22 (6) | 53 (26) | |
| Flu + Cy + alemtuzumab | 416 (25) | 334 (30) | 82 (24) | 0 (0) | |
| Cy + ATG | 117 (7) | 95 (9) | 21 (6) | 1 (0.5) | |
| Other | 299 (18) | 174 (16) | 75 (22) | 50 (24) | |
| Stem cell source, n (%) | <.001 | ||||
| Bone marrow | 979 (59) | 666 (60) | 202 (59) | 111 (54) | |
| Peripheral blood | 663 (40) | 439 (40) | 136 (40) | 88 (43) | |
| BM + PB | 10 (1) | 1 (0) | 2 (1) | 7 (3) | |
| Serotherapy for in vivo TCD, n (%) | <.001 | ||||
| ATG | 1017 (63) | 685 (63) | 208 (64) | 124 (61) | |
| Alemtuzumab | 470 (29) | 372 (34) | 95 (29) | 3 (1) | |
| No serotherapy | 136 (8) | 35 (3) | 23 (7) | 78 (38) | |
| Missing | 29 | 14 | 14 | 1 | |
| GVHD prophylaxis, n (%) | <.001 | ||||
| CNI + MTX | 708 (43) | 540 (49) | 168 (49) | 0 (0) | |
| PT-Cy based | 274 (17) | 36 (3) | 32 (9) | 206 (100) | |
| Others | 670 (40) | 530 (48) | 140 (42) | 0 (0) |
| Characteristic . | Total N = 1652 . | MUD N = 1106 . | MMUD N = 340 . | Haplo N = 206 . | P value . |
|---|---|---|---|---|---|
| Median age at transplant, y (IQR) | 20.4 (11.2-40.1) | 21 (11.7-42.3) | 17.8 (10.4-34.8) | 20.9 (10.7-37.5) | .016 |
| Sex, n (%) | .756 | ||||
| Male | 953 (58) | 631 (57) | 201 (59) | 121 (59) | |
| Female | 699 (42) | 475 (43) | 139 (41) | 85 (41) | |
| KPS, n (%) | .319 | ||||
| ≥90 | 1116 (73) | 753 (74) | 232 (74) | 131 (67) | |
| <90 | 412 (27) | 267 (26) | 80 (26) | 65 (33) | |
| Missing | 124 | 86 | 28 | 10 | |
| Year of transplant, median (IQR) | 2017 (2014-2019) | 2017 (2014-2019) | 2016 (2014-2019) | 2018 (2017-2020) | <.001 |
| Interval diagnosis to transplant in months, median (IQR) | 8.7 (4.8-16.6) | 8.1 (4.3-14.3) | 10.4 (6.2-19.6) | 9.2 (4.8-18.5) | <.001 |
| Donor–recipient CMV serostatus, n (%) | <.001 | ||||
| Positive/positive | 740 (46) | 436 (40) | 164 (50) | 140 (72) | |
| Positive/negative | 97 (6) | 66 (6) | 20 (6) | 11 (6) | |
| Negative/positive | 397 (25) | 277 (26) | 96 (30) | 24 (12) | |
| Negative/negative | 370 (23) | 304 (28) | 46 (14) | 20 (10) | |
| Missing | 48 | 23 | 14 | 11 | |
| HCT-CI, n (%) | .522 | ||||
| Low | 894 (69) | 597 (69) | 178 (69) | 119 (70) | |
| Intermediate | 201 (16) | 126 (15) | 48 (18) | 27 (16) | |
| High | 194 (15) | 136 (16) | 33 (13) | 25 (14) | |
| Missing | 363 | 247 | 81 | 35 | |
| Median age of donor, y (range) | 29.4 (23.6-36.8) | 28.2 (23.4-34.4) | 29.5 (23.6-37.5) | 36.3 (27.2-45.9) | <.001 |
| Female donor to male recipient, n (%) | 254 (16) | 129 (12) | 71 (21) | 54 (26) | <.001 |
| TBI in conditioning, n (%) | <.001 | ||||
| Yes | 495 (31) | 253 (23) | 103 (31) | 139 (69) | |
| No | 1122 (69) | 834 (77) | 224 (69) | 64 (31) | |
| Missing | 35 | 19 | 13 | 3 | |
| TBI dose, n (%) | <.001 | ||||
| 2 Gy | 430 (87) | 239 (94) | 87 (84) | 104 (75) | |
| >2 Gy | 65 (13) | 14 (6) | 16 (16) | 35 (25) | |
| Conditioning regime,∗ n (%) | <.001 | ||||
| Flu + Cy + ATG + TBI | 287 (18) | 156 (14) | 56 (17) | 75 (36.5) | |
| Flu + Cy + ATG | 402 (24) | 291 (26) | 84 (25) | 27 (13) | |
| Flu + Cy + TBI | 131 (8) | 56 (5) | 22 (6) | 53 (26) | |
| Flu + Cy + alemtuzumab | 416 (25) | 334 (30) | 82 (24) | 0 (0) | |
| Cy + ATG | 117 (7) | 95 (9) | 21 (6) | 1 (0.5) | |
| Other | 299 (18) | 174 (16) | 75 (22) | 50 (24) | |
| Stem cell source, n (%) | <.001 | ||||
| Bone marrow | 979 (59) | 666 (60) | 202 (59) | 111 (54) | |
| Peripheral blood | 663 (40) | 439 (40) | 136 (40) | 88 (43) | |
| BM + PB | 10 (1) | 1 (0) | 2 (1) | 7 (3) | |
| Serotherapy for in vivo TCD, n (%) | <.001 | ||||
| ATG | 1017 (63) | 685 (63) | 208 (64) | 124 (61) | |
| Alemtuzumab | 470 (29) | 372 (34) | 95 (29) | 3 (1) | |
| No serotherapy | 136 (8) | 35 (3) | 23 (7) | 78 (38) | |
| Missing | 29 | 14 | 14 | 1 | |
| GVHD prophylaxis, n (%) | <.001 | ||||
| CNI + MTX | 708 (43) | 540 (49) | 168 (49) | 0 (0) | |
| PT-Cy based | 274 (17) | 36 (3) | 32 (9) | 206 (100) | |
| Others | 670 (40) | 530 (48) | 140 (42) | 0 (0) |
P values were obtained using the χ2 test for categorical variables and the Kruskal–Wallis test for continuous data.
BM, bone marrow; CMV, cytomegalovirus; CNI, calcineurin inhibitors; Cy, cyclophosphamide; FCA, fludarabine, cyclophosphamide, ATG; Flu, fludarabine; HCT-CI, hematopoietic cell transplantation-comorbidity index; MTX, methotrexate; PB, peripheral blood.
The most frequently used doses were: Flu 30 mg/m2 × 4 (days −6 to −3), Cy 300 mg/m2 or 30 mg/kg × 4 (days −6 to −3), ATG 3.75 mg/kg × 2 (days −4 to −3), and TBI 2 Gy (day −1) (FCA TBI regimen); Flu 30 mg/m2 × 4 (days −6 to −3), Cy 300 mg/m2 × 4 (days −6 to −3), and ATG (5-10 mg/kg) (FCA regimen); Flu 30 mg/m2 × 4 (days −6 to −2), Cy 14.5 mg/kg × 2 (days −7 to −6), and TBI 2 Gy (day −1) (Baltimore protocol); Flu 30 mg/m2 (days −6 to −3), Cy 300 mg/m2 × 4 (days −6 to −3), and alemtuzumab 0.2 mg/kg × 5 (days −7 to −3) (FCC regimen), and Cy 50 mg/kg × 4 (days −5 to −2) and ATG (5-10 mg/kg). ATG schedule and dosage are presented with thymoglobulin (Genzyme, a Sanofi company).